Reliq Health Technologies (OTC:RQHTF) is a digital health company that provides innovative SaaS solutions to the $100 Billion Virtual Care market. Reliq’s proprietary iUGO Care platform supports Remote Patient Monitoring, Telemedicine, Chronic Care Management and Transitional Care Management.
The market need is met
US healthcare costs exceeded $3.6 Trillion in 2019. Chronic diseases like diabetes, hypertension, congestive heart failure and COPD account for over 75% of healthcare spending or 18% of US GDP, as these patients frequently develop complications that lead to costly hospitalizations.
The Centers for Medicare & Medicaid Services (CMS) have recently transitioned from fee for service to value-based payments, so healthcare providers are now compensated based on patient health outcomes, with significant financial penalties for preventable patient hospital admissions and ER visits.
Reliq’s iUGO Care software platform provides clinicians with real-time access to remote patient monitoring data, allowing for timely interventions to prevent costly hospital admissions and ER visits. The average clinical practice can generate new revenue of over $315 USD per patient per month in payments from CMS by deploying iUGO Care.
Hospital admissions are reduced by over 90% in chronic disease patients using iUGO Care, and the average cost to the healthcare system is reduced to <$4,000 USD/patient/year from over $20,000 USD per patient per year.
Reliq has over 50 US clients and a pipeline of more than 500,000 chronic disease patients. The Company expects to achieve cashflow positive in Q1 2021 and profitability in Q2 2021. By the end of 2021, Gross Margins will exceed 75% and EBITDA margins will be over 45%.
Reliq appears to be ahead of schedule on their business development timeline. They have met the goal of US roll out in 2020, added orders that equate to 7.8m in potential sales which far exceeds their 2m revenue target by the end of the year.
Currently projecting modest revenue profits for 2021 of 11m, 2022 or 32M and 65M in 2023. Following their original timeline they should hit 100m net revenue by 2024 providing a valuation of $1b. I believe their progress to date would likely move the timeline up provided they can execute. This will be over $1 by end of January.
Long term, with listing on to Nasdaq and broad adaptation of the products they are $10 in 2-4 years. I first mentioned this ticker 2 weeks ago when it was 25 cents. Hit 55 cents today. Company will news and marketing programs going forward in the next 2 weeks. Steady growth and fairly low trading volume means this could really take off if it starts to get some mainstream attention.